Healthcare Is Wall Street’s New Safe Haven — And That’s Spectacular News for Exhibitors at HIMSS, HLTH, and ViVE

On February 13, 2026, while the technology sector stumbled through another session of earnings anxiety and tariff uncertainty, hospital stocks surged to the top of the S&P 500. HCA Healthcare and Universal Health Services did not merely hold steady; they led, posting gains that placed them among the index’s strongest performers on a day when most sectors traded sideways or worse. Healthcare has become Wall Street’s most compelling safe haven—and the capital flowing into the space is about to reshape every healthcare trade show from HIMSS to Arab Health.

Why Healthcare Decoupled from Tech — and What It Means for Show Budgets

For a decade, healthcare stocks correlated with the broader market. That correlation has broken—structurally. HCA Healthcare (186 hospitals, 2,000 sites of care) and Universal Health Services (361 inpatient facilities) benefit from demographic tailwinds that no tariff policy or Fed decision can reverse. America is aging. Emergency departments are overflowing. Elective surgery volumes have exceeded 2019 baselines. CMS reimbursement has stabilized enough for hospital CFOs to plan multi-year capital expenditure programs.

For exhibitors, the math is straightforward. When hospital stocks rise, operating budgets expand. The companies walking the floors at HIMSS, HLTH, and ViVE in 2026 are riding investor confidence that translates directly into procurement authority.

The $4.6 Billion Community Health Pipeline

Wall Street enthusiasm alone does not deploy EHR systems. Public investment does—and Congress just delivered. Legislation providing $4.6 billion for community health centers extends funding for the 1,400-plus FQHCs serving more than 30 million patients annually, while also extending telehealth flexibilities and hospital-at-home waivers.

FQHCs are among healthcare’s most active technology buyers because they operate in underserved markets where efficiency is existential. The funding extension provides multi-year budget certainty, meaning procurement officers can commit to longer contracts rather than cautious year-to-year purchases.

The Measles Outbreak Creates Urgent Exhibitor Demand

The CDC has confirmed 588 measles cases in 2026 so far—more in six weeks than the country typically records in an entire year. The outbreak represents the most significant failure of childhood vaccination coverage in a generation. For exhibitors in public health surveillance, vaccine management, and laboratory diagnostics, it is an urgent market catalyst.

Public health departments are discovering their surveillance systems were built for a world where measles was eliminated—not for sustained outbreaks involving hundreds of cases and thousands of contacts. Modern surveillance platforms are no longer roadmap items. They are emergency procurement priorities.

“When 588 measles cases arrive in six weeks—in a country that declared the disease eliminated in 2000—the gap between the surveillance infrastructure we have and the infrastructure we need becomes impossible to ignore. Every booth at HIMSS and HLTH should reflect that reality.”

Exhibitors should foreground outbreak response capabilities and integration with the CDC’s National Notifiable Diseases Surveillance System. Buyers are evaluating against an active crisis. The diagnostics angle matters too—measles diagnosis requires specific IgM antibody testing that not every hospital laboratory maintains in-house, creating heightened interest at shows like FIME.

Telehealth and Hospital-at-Home Extensions Reshape HIMSS 2026

The telehealth extension allows Medicare to reimburse without geographic restrictions, with audio-only visits remaining covered. Exhibitors at the ATA conference and HIMSS can now sell multi-year contracts rather than pilot programs. The hospital-at-home waiver is equally significant: more than 300 hospitals across 130 health systems have participated, with patient satisfaction exceeding inpatient benchmarks. CMS now views the model as permanent, moving remote monitoring and patient engagement from niche to mainstream at HIMSS 2026.

The $600 Million Grants Battle

A federal court temporarily blocked the Trump administration from cutting $600 million in public health grants to four Democratic-led states. The grants fund chronic disease prevention and emergency preparedness. The injunction preserves funding for now, but the legal battle continues.

For exhibitors, this creates a bifurcated reality: procurement decisions deferred in affected states, but the ruling signals the legal system is checking disruptions. Prepare for conversations about contract flexibility and modular pricing that scales with funding variability.

The Kaiser Strike Factor — What West Coast Exhibitors Should Know

Three thousand UFCW members have joined an ongoing Kaiser Permanente strike across West Coast operations, disrupting one of the nation’s largest integrated health systems and most sophisticated HIMSS technology purchasers. Kaiser’s operational attention shifts to labor negotiations, potentially delaying Q1/Q2 procurement. Meanwhile, traveling nurses filling Kaiser’s gaps are drawn from the same pool other systems rely on, squeezing non-Kaiser hospitals into accelerating investments in workforce optimization technology. The strike may paradoxically increase demand from non-Kaiser buyers.

Show-by-Show Impact Analysis

The impact varies by show focus, attendee profile, and geographic context. Here is how each of the most consequential healthcare trade shows in 2026 is positioned.

HIMSS 2026 (Orlando, FL)

HIMSS remains the undisputed flagship of health IT. The $4.6 billion FQHC extension creates a buyer segment with active procurement mandates. Telehealth and hospital-at-home extensions remove regulatory uncertainty. The measles outbreak ensures public health informatics will command outsized attention. Book larger than 2025 and staff with clinical experts who can speak to outbreak response.

HLTH 2026 (Las Vegas, NV)

HLTH is where healthcare business strategy meets innovation capital. When hospital stocks lead the S&P 500, buyers operate from confidence rather than caution. Health system executives and digital health investors will arrive with larger budgets. Lean into ROI-focused messaging—HLTH attendees are receptive to business case arguments when the market validates healthcare as a growth sector.

ViVE 2026 (Nashville, TN)

ViVE’s attendees make hands-on technology decisions—which remote monitoring vendor to deploy, which telehealth platform to integrate. The $4.6 billion pipeline and hospital-at-home certainty give them confidence to commit on the show floor. Bring working product demonstrations, not slide decks.

ATA (American Telemedicine Association) Conference

No show benefits more directly from the telehealth extension. ATA 2026 transforms from a conference worried about regulatory sunset into one planning for scale. The measles outbreak adds urgency—telehealth is proving critical for triaging suspected cases and delivering vaccine education.

FIME (Florida International Medical Expo)

FIME connects US companies with Latin American and Caribbean buyers grappling with similar declining vaccination rates and urgent diagnostics needs.

Arab Health (Dubai, UAE)

Gulf Cooperation Council countries are among the most active buyers of American healthcare technology. Wall Street’s enthusiasm reinforces US health IT companies as stable partners, and the hospital-at-home model interests Gulf systems seeking decentralized care. Exhibitors with CMS validation data carry a credibility advantage.

What Exhibitors Should Do Now

The convergence of market tailwinds, legislative certainty, and public health urgency creates a flywheel that exhibitors have not seen since the post-pandemic surge—except this cycle is structural, not crisis-driven.

• Upsize your booth footprint. The 2026 buyer environment is meaningfully stronger than 2025. Attendees have budget authority validated by Wall Street, funded by Congress, and motivated by a public health crisis.
• Lead with telehealth and hospital-at-home. These are reimbursed, regulatory-supported models. The “what if reimbursement expires?” objection is gone.
• Prepare a public health narrative. The measles outbreak has elevated surveillance and outbreak response technology to mainstream priorities.
• Staff for policy conversations. Teams fluent in CMS waivers and FQHC reimbursement will outperform product-only teams.
• Account for labor dynamics. The Kaiser strike shifts buyer priorities toward workforce optimization technology.
• Target FQHCs. The $4.6 billion extension creates a well-funded buyer cohort that enterprise-focused exhibitors often overlook.

The Bottom Line

Healthcare’s emergence as Wall Street’s safe haven is not a single-session anomaly. The $4.6 billion community health investment provides funding certainty. The telehealth and hospital-at-home extensions provide regulatory certainty. The measles outbreak provides demand urgency. And the Kaiser labor actions accelerate adoption of the very technologies that exhibitors are bringing to market.

For healthcare trade show exhibitors, February 2026 is not a moment to play it safe. The market is telling you—in the language of stock prices, legislative votes, and CDC case counts—that the buyers are ready. The exhibitors who match that energy on the show floor will be the ones converting badge scans into purchase orders when the convention center lights go dark.

Sources: FinancialContent/MarketMinute, Feb. 13, 2026; Alston & Bird Health Care Week in Review; CDC measles surveillance data, 2026; CMS Acute Hospital Care at Home program data; Congressional Budget Office cost estimates for community health center reauthorization.